Adaptive Biotechnologies (ADPT) Research & Development (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Research & Development data on file, last reported at $23.6 million in Q1 2026.

• Quarterly Research & Development fell 2.4% year-over-year to $23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.2 million (down 3.84% YoY) and the FY2025 annual result came in at $93.8 million, down 8.92% from the prior year.
• Research & Development improved to $23.6 million in Q1 2026 per ADPT's latest filing, from $21.8 million in the prior quarter.
• The five-year high for Research & Development was $37.8 million in Q1 2022, with the low at $21.8 million in Q4 2025.
• Average Research & Development over 5 years is $28.5 million, with a median of $28.5 million recorded in 2023.
• Year-over-year, Research & Development increased 12.04% in 2022 and decreased 21.35% in 2024.
• Adaptive Biotechnologies' Research & Development stood at $31.2 million in 2022, then fell by 7.93% to $28.7 million in 2023, then retreated by 19.32% to $23.2 million in 2024, then retreated by 6.16% to $21.8 million in 2025, then climbed by 8.55% to $23.6 million in 2026.
• Business Quant data shows ADPT's Research & Development at $23.6 million in Q1 2026, $21.8 million in Q4 2025, and $23.7 million in Q3 2025.